Demonstrating an end to end mAb process with final concentration over 200 g/L
Subcutaneous (SC) administration of monoclonal antibodies (mAbs) has several benefits over intravenous (IV) infusion including being less invasive, requiring shorter administration times, and the possibility for self-administration. However, to achieve the dosage needed within the volume limitations of SC administration, the formulation must be highly concentrated, often over 100 g/L and sometimes upwards of 200 g/L. Here we demonstrate, using only our products, how you can achieve a final mAb concentration of over 200 g/L whilst maintaining key quality attributes.
